Related Experiment Video
Updated: May 11, 2026

Cortical Neurogenesis: Transitioning from Advances in the Laboratory to Cell-Based Therapies
Published on: July 19, 2007
New drugs and indications in 2012. Sluggish progress, timid measures to protect patients
Abstract:
The therapeutic advances identified in 2012 were minimal, and 15 new drugs or indications are dangerous. The dearth of improvement in patient care contrasts with the sometimes disproportionately high prices agreed upon for drugs, especially in oncology. The few steps taken by health authorities that benefited patients, mainly by withdrawing or revoking reimbursement for drugs with an unfavourable harm-benefit balance, were insufficient in view of the constant pressure from the pharmaceutical industry to sell ever more drugs.
Related Concept Videos
Drug Regulation
FDA Approved Drugs: Changes to Approved Drugs
Drug Products: Biologics, Biosimilars and Interchangeables
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Clinical Trials: Overview
